Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
50
RMD Quote, Financials, Valuation and Earnings
Last price:
$249.23
Seasonality move
:
4.2%
Day range:
$242.54 - $247.29
52-week range:
$199.92 - $293.81
Dividend yield:
0.92%
P/E ratio:
25.11x
P/S ratio:
6.87x
P/B ratio:
5.85x
Volume:
773.9K
Avg. volume:
906.7K
1-year change:
5.91%
Market cap:
$35.8B
Revenue:
$5.1B
EPS (TTM):
$9.77
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RMD
ResMed, Inc.
|
$1.4B | $2.71 | 8.96% | 16.17% | $291.80 |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 8.09% | 61.69% | $144.43 |
|
BDX
Becton, Dickinson & Co.
|
$5.2B | $2.81 | -0.31% | 169.42% | $204.83 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 15.75% | 105.65% | $125.86 |
|
SYK
Stryker Corp.
|
$7.1B | $4.39 | 10.64% | 210.62% | $428.11 |
|
WST
West Pharmaceutical Services, Inc.
|
$795.7M | $1.84 | 6.25% | 3.35% | $345.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RMD
ResMed, Inc.
|
$245.36 | $291.80 | $35.8B | 25.11x | $0.60 | 0.92% | 6.87x |
|
ABT
Abbott Laboratories
|
$126.45 | $144.43 | $219.9B | 15.86x | $0.59 | 1.87% | 5.04x |
|
BDX
Becton, Dickinson & Co.
|
$198.96 | $204.83 | $56.8B | 34.13x | $1.05 | 2.1% | 2.62x |
|
BSX
Boston Scientific Corp.
|
$95.48 | $125.86 | $141.5B | 51.07x | $0.00 | 0% | 7.37x |
|
SYK
Stryker Corp.
|
$348.79 | $428.11 | $133.4B | 45.80x | $0.88 | 0.98% | 5.53x |
|
WST
West Pharmaceutical Services, Inc.
|
$279.03 | $345.71 | $20.1B | 41.33x | $0.22 | 0.31% | 6.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RMD
ResMed, Inc.
|
12.15% | 0.549 | 2.12% | 1.89x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | 5.99% | 1.12x |
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.449 | 37.48% | 0.47x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
SYK
Stryker Corp.
|
44.02% | 0.442 | 12.35% | 0.97x |
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.594 | 1.61% | 2.02x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
SYK
Stryker Corp.
|
$3.7B | $1.4B | 7.89% | 14.06% | 22.52% | $1.4B |
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
ResMed, Inc. vs. Competitors
-
Which has Higher Returns RMD or ABT?
Abbott Laboratories has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.07%. ResMed, Inc.'s return on equity of 25.6% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital RMDResMed, Inc.60.56% $2.37 $7B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About RMD or ABT?
ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 18.93%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 14.22%. Given that ResMed, Inc. has higher upside potential than Abbott Laboratories, analysts believe ResMed, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings RMDResMed, Inc.8 7 1 ABTAbbott Laboratories15 7 0 -
Is RMD or ABT More Risky?
ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock RMD or ABT?
ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.92%. Abbott Laboratories offers a yield of 1.87% to investors and pays a quarterly dividend of $0.59 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RMD or ABT?
ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. ResMed, Inc.'s net income of $348.5M is lower than Abbott Laboratories's net income of $1.6B. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.11x while Abbott Laboratories's PE ratio is 15.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.87x versus 5.04x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMDResMed, Inc.6.87x 25.11x $1.3B $348.5M ABTAbbott Laboratories5.04x 15.86x $11.4B $1.6B
-
Which has Higher Returns RMD or BDX?
Becton, Dickinson & Co. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 8.37%. ResMed, Inc.'s return on equity of 25.6% beat Becton, Dickinson & Co.'s return on equity of 6.6%.
Company Gross Margin Earnings Per Share Invested Capital RMDResMed, Inc.60.56% $2.37 $7B BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B -
What do Analysts Say About RMD or BDX?
ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 18.93%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 2.95%. Given that ResMed, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe ResMed, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings RMDResMed, Inc.8 7 1 BDXBecton, Dickinson & Co.3 9 0 -
Is RMD or BDX More Risky?
ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.236, suggesting its less volatile than the S&P 500 by 76.383%.
-
Which is a Better Dividend Stock RMD or BDX?
ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.92%. Becton, Dickinson & Co. offers a yield of 2.1% to investors and pays a quarterly dividend of $1.05 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RMD or BDX?
ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. ResMed, Inc.'s net income of $348.5M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.11x while Becton, Dickinson & Co.'s PE ratio is 34.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.87x versus 2.62x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMDResMed, Inc.6.87x 25.11x $1.3B $348.5M BDXBecton, Dickinson & Co.2.62x 34.13x $5.9B $493M
-
Which has Higher Returns RMD or BSX?
Boston Scientific Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.91%. ResMed, Inc.'s return on equity of 25.6% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital RMDResMed, Inc.60.56% $2.37 $7B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About RMD or BSX?
ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 18.93%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.82%. Given that Boston Scientific Corp. has higher upside potential than ResMed, Inc., analysts believe Boston Scientific Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMDResMed, Inc.8 7 1 BSXBoston Scientific Corp.25 2 0 -
Is RMD or BSX More Risky?
ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock RMD or BSX?
ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.92%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RMD or BSX?
ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. ResMed, Inc.'s net income of $348.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.11x while Boston Scientific Corp.'s PE ratio is 51.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.87x versus 7.37x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMDResMed, Inc.6.87x 25.11x $1.3B $348.5M BSXBoston Scientific Corp.7.37x 51.07x $5.1B $755M
-
Which has Higher Returns RMD or SYK?
Stryker Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.18%. ResMed, Inc.'s return on equity of 25.6% beat Stryker Corp.'s return on equity of 14.06%.
Company Gross Margin Earnings Per Share Invested Capital RMDResMed, Inc.60.56% $2.37 $7B SYKStryker Corp.61.86% $2.22 $38.9B -
What do Analysts Say About RMD or SYK?
ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 18.93%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 22.74%. Given that Stryker Corp. has higher upside potential than ResMed, Inc., analysts believe Stryker Corp. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMDResMed, Inc.8 7 1 SYKStryker Corp.13 9 0 -
Is RMD or SYK More Risky?
ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 10.974%.
-
Which is a Better Dividend Stock RMD or SYK?
ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.92%. Stryker Corp. offers a yield of 0.98% to investors and pays a quarterly dividend of $0.88 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RMD or SYK?
ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. ResMed, Inc.'s net income of $348.5M is lower than Stryker Corp.'s net income of $859M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.11x while Stryker Corp.'s PE ratio is 45.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.87x versus 5.53x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMDResMed, Inc.6.87x 25.11x $1.3B $348.5M SYKStryker Corp.5.53x 45.80x $6.1B $859M
-
Which has Higher Returns RMD or WST?
West Pharmaceutical Services, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 17.41%. ResMed, Inc.'s return on equity of 25.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.
Company Gross Margin Earnings Per Share Invested Capital RMDResMed, Inc.60.56% $2.37 $7B WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B -
What do Analysts Say About RMD or WST?
ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 18.93%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 23.9%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RMDResMed, Inc.8 7 1 WSTWest Pharmaceutical Services, Inc.11 3 0 -
Is RMD or WST More Risky?
ResMed, Inc. has a beta of 0.876, which suggesting that the stock is 12.416% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.
-
Which is a Better Dividend Stock RMD or WST?
ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.92%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RMD or WST?
ResMed, Inc. quarterly revenues are $1.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. ResMed, Inc.'s net income of $348.5M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, ResMed, Inc.'s price-to-earnings ratio is 25.11x while West Pharmaceutical Services, Inc.'s PE ratio is 41.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.87x versus 6.74x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RMDResMed, Inc.6.87x 25.11x $1.3B $348.5M WSTWest Pharmaceutical Services, Inc.6.74x 41.33x $804.3M $140M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
